By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan/iza-bren) for a new indication in adult patients with relapsed/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate (ADC).
Regulatory Approval Summary
| Component | Detail |
|---|---|
| Agency | China National Medical Products Administration (NMPA) |
| Product | Yizekang (izalontamab brengitecan/iza-bren) |
| Approval Type | Full approval for new indication |
| Indication | Relapsed/metastatic esophageal squamous cell carcinoma (ESCC) |
| Patient Population | Adults who failed PD-1/PD-L1 inhibitors + platinum-based chemotherapy |
| Innovation Status | World’s first EGFR×HER3 bispecific ADC |
| Classification | First-in-class (FIC) Class 1 therapeutic biologic |
Product Profile & Mechanism
- Molecule Type: Bispecific antibody-drug conjugate (ADC)
- Targets: Dual targeting of EGFR and HER3 receptors
- Payload: Cytotoxic agent delivered specifically to tumor cells expressing both targets
- Differentiation: Simultaneous blockade of two key oncogenic pathways enhances anti-tumor activity and overcomes resistance mechanisms
- Intellectual Property: Protected by composition-of-matter and method-of-use patents extending to 2042+
Regulatory Timeline & Pipeline Progression
| Milestone | Date | Indication |
|---|---|---|
| First Approval | June 2026 | Relapsed/metastatic nasopharyngeal carcinoma (after ≥2 prior lines including PD-1/PD-L1 inhibitors) |
| Second Approval | July 2026 | Relapsed/metastatic esophageal squamous cell carcinoma |
| NDA Accepted | Pending | Locally advanced or metastatic triple-negative breast cancer |
| Future Development | Ongoing | Additional solid tumor indications leveraging dual EGFR×HER3 targeting |
Market Context & Therapeutic Need
- Esophageal Cancer Burden: China accounts for approximately 50% of global esophageal cancer cases, with ESCC representing 90% of cases in the region
- Treatment Gap: Limited options for patients progressing after standard PD-1/PD-L1 + chemotherapy regimens
- Survival Challenge: Median overall survival in refractory ESCC typically less than 6 months
- Target Expression: High co-expression of EGFR and HER3 in ESCC tumors provides strong rationale for bispecific approach
Commercial Strategy & Market Impact
- Addressable Population: Estimated 45,000+ ESCC patients annually in China eligible for third-line treatment
- Pricing Position: Premium pricing expected given first-in-class status and significant unmet medical need
- Reimbursement Pathway: Priority review designation supports accelerated inclusion in national reimbursement drug list (NRDL)
- Global Expansion: Clinical trials planned for international markets following successful China launch
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, commercial expectations, and market opportunities for Yizekang. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and international regulatory requirements.-Fineline Info & Tech